niacinamide has been researched along with Renal Insufficiency, Chronic in 17 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ischemia-reperfusion injury (IRI) is a model for AKI, which results in tubular damage, dysfunction of the mitochondria and autophagy, and in decreased cellular nicotinamide adenine dinucleotide (NAD+) with progressing fibrosis resulting in CKD." | 8.02 | Effect of NAD+ boosting on kidney ischemia-reperfusion injury. ( Andersen, CB; Egstrand, S; Lewin, E; Mace, ML; Morevati, M; Nordholm, A; Olgaard, K; Salmani, R, 2021) |
| " However, niacin can cause flushing and niacinamide probably cause thrombocytopenia." | 4.90 | Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis. ( Feng, L; He, YM; Huo, DM; Liao, YH; Yang, ZH, 2014) |
| " Ischemia-reperfusion injury (IRI) is a model for AKI, which results in tubular damage, dysfunction of the mitochondria and autophagy, and in decreased cellular nicotinamide adenine dinucleotide (NAD+) with progressing fibrosis resulting in CKD." | 4.02 | Effect of NAD+ boosting on kidney ischemia-reperfusion injury. ( Andersen, CB; Egstrand, S; Lewin, E; Mace, ML; Morevati, M; Nordholm, A; Olgaard, K; Salmani, R, 2021) |
| " Treatment discontinuation due to adverse events was 1." | 2.84 | Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. ( Brazier, M; Brisset, S; Choukroun, G; El Esper, N; Fournier, A; Kamel, S; Lemaire-Hurtel, AS; Lenglet, A; Liabeuf, S; Mansour, J; Mary, A; Massy, ZA; Mentaverri, R, 2017) |
| "Hyperphosphatemia is thought to be a central-risk factor for CKD-MBD." | 1.42 | Niacin and Chronic Kidney Disease. ( Masuda, M; Miyamoto, K; Segawa, H; Takeda, E; Taketani, Y; Tatsumi, S; Yamamoto, H; Yamanaka-Okumura, H, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 7 (41.18) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, W | 1 |
| Rong, G | 1 |
| Gu, J | 1 |
| Fan, C | 1 |
| Guo, T | 1 |
| Jiang, T | 1 |
| Deng, W | 1 |
| Xie, J | 1 |
| Su, Z | 1 |
| Yu, Q | 1 |
| Mai, J | 1 |
| Zheng, R | 1 |
| Chen, X | 1 |
| Tang, X | 1 |
| Zhang, J | 1 |
| Takahashi, R | 1 |
| Kanda, T | 1 |
| Komatsu, M | 1 |
| Itoh, T | 1 |
| Minakuchi, H | 1 |
| Urai, H | 1 |
| Kuroita, T | 1 |
| Shigaki, S | 1 |
| Tsukamoto, T | 1 |
| Higuchi, N | 1 |
| Ikeda, M | 1 |
| Yamanaka, R | 1 |
| Yoshimura, N | 1 |
| Ono, T | 1 |
| Yukioka, H | 1 |
| Hasegawa, K | 1 |
| Tokuyama, H | 1 |
| Wakino, S | 1 |
| Itoh, H | 1 |
| Kalantari, S | 1 |
| Chashmniam, S | 1 |
| Nafar, M | 1 |
| Samavat, S | 1 |
| Rezaie, D | 1 |
| Dalili, N | 1 |
| Faivre, A | 1 |
| Katsyuba, E | 1 |
| Verissimo, T | 1 |
| Lindenmeyer, M | 1 |
| Rajaram, RD | 1 |
| Naesens, M | 1 |
| Heckenmeyer, C | 1 |
| Mottis, A | 1 |
| Feraille, E | 1 |
| Cippà, P | 1 |
| Cohen, C | 1 |
| Longchamp, A | 1 |
| Allagnat, F | 1 |
| Rutkowski, JM | 1 |
| Legouis, D | 1 |
| Auwerx, J | 1 |
| de Seigneux, S | 1 |
| Kumakura, S | 1 |
| Sato, E | 1 |
| Sekimoto, A | 1 |
| Hashizume, Y | 1 |
| Yamakage, S | 1 |
| Miyazaki, M | 1 |
| Ito, S | 1 |
| Harigae, H | 1 |
| Takahashi, N | 1 |
| Morevati, M | 1 |
| Egstrand, S | 1 |
| Nordholm, A | 1 |
| Mace, ML | 1 |
| Andersen, CB | 1 |
| Salmani, R | 1 |
| Olgaard, K | 1 |
| Lewin, E | 1 |
| Fouque, D | 1 |
| Vervloet, M | 1 |
| Ketteler, M | 1 |
| Kaesler, N | 1 |
| Goettsch, C | 1 |
| Weis, D | 1 |
| Schurgers, L | 1 |
| Hellmann, B | 1 |
| Floege, J | 1 |
| Kramann, R | 1 |
| Saurette, M | 1 |
| Alexander, RT | 1 |
| Lenglet, A | 3 |
| Fabresse, N | 1 |
| Taupin, M | 1 |
| Gomila, C | 1 |
| Liabeuf, S | 3 |
| Kamel, S | 3 |
| Alvarez, JC | 1 |
| Drueke, TB | 1 |
| Massy, ZA | 3 |
| Ix, JH | 2 |
| Isakova, T | 1 |
| Larive, B | 1 |
| Raphael, KL | 1 |
| Raj, DS | 1 |
| Cheung, AK | 1 |
| Sprague, SM | 1 |
| Fried, LF | 1 |
| Gassman, JJ | 1 |
| Middleton, JP | 1 |
| Flessner, MF | 1 |
| Block, GA | 1 |
| Wolf, M | 1 |
| Yeung, WG | 1 |
| Toussaint, ND | 1 |
| Badve, SV | 1 |
| He, YM | 1 |
| Feng, L | 1 |
| Huo, DM | 1 |
| Yang, ZH | 1 |
| Liao, YH | 1 |
| Taketani, Y | 1 |
| Masuda, M | 1 |
| Yamanaka-Okumura, H | 1 |
| Tatsumi, S | 1 |
| Segawa, H | 1 |
| Miyamoto, K | 1 |
| Takeda, E | 1 |
| Yamamoto, H | 1 |
| El Esper, N | 1 |
| Brisset, S | 1 |
| Mansour, J | 1 |
| Lemaire-Hurtel, AS | 2 |
| Mary, A | 2 |
| Brazier, M | 1 |
| Mentaverri, R | 1 |
| Choukroun, G | 1 |
| Fournier, A | 1 |
| Ginsberg, C | 1 |
| Bodeau, S | 1 |
| Louvet, L | 1 |
| Boullier, A | 1 |
| Jonet, A | 1 |
| Sonnet, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease (TOP-CKD)[NCT04258397] | Phase 2 | 200 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE[NCT02258074] | Phase 2 | 205 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline to 12 months in FGF23 level. (NCT02258074)
Timeframe: Baseline to 12 months
| Intervention | pg/ml (Mean) |
|---|---|
| Lanthanum Carbonate + Nicotinamide | .047 |
| Lanthanum Carbonate + Nicotinamide Placebo | -.003 |
| Lanthanum Carbonate Placebo and Nicotinamide | .193 |
| Lanthanum Carbonate Placebo and Nicotinamide Placebo | .138 |
Change from Baseline to 12 months in serum phosphate level (NCT02258074)
Timeframe: Baseline to 12 months
| Intervention | mg/dl (Mean) |
|---|---|
| Lanthanum Carbonate + Nicotinamide | 0.06 |
| Lanthanum Carbonate + Nicotinamide Placebo | 0.06 |
| Lanthanum Carbonate Placebo and Nicotinamide | 0.12 |
| Lanthanum Carbonate Placebo and Nicotinamide Placebo | 0.12 |
4 reviews available for niacinamide and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.
Topics: Animals; Carrier Proteins; Chelating Agents; Drug Therapy, Combination; Gastrointestinal Tract; Huma | 2018 |
Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis.
Topics: Flushing; Humans; Lipoproteins, HDL; Niacin; Niacinamide; Phosphorus; Randomized Controlled Trials a | 2014 |
Nicotinamide and phosphate homeostasis in chronic kidney disease.
Topics: Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Homeostasis; Humans; Hyperphosphatemia; N | 2016 |
N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin.
Topics: Animals; Humans; Niacinamide; Renal Insufficiency, Chronic; Toxins, Biological; Uremia | 2016 |
3 trials available for niacinamide and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?
Topics: Aged; Endotoxemia; Endotoxins; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Human | 2019 |
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Topics: Adult; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerul | 2019 |
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Topics: Adult; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerul | 2019 |
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Topics: Adult; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerul | 2019 |
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Topics: Adult; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerul | 2019 |
Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.
Topics: Adult; Aged; Female; Humans; Hyperphosphatemia; Male; Middle Aged; Niacinamide; Phosphorus; Prospect | 2017 |
10 other studies available for niacinamide and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Nicotinamide N-methyltransferase ameliorates renal fibrosis by its metabolite 1-methylnicotinamide inhibiting the TGF-β1/Smad3 pathway.
Topics: Animals; Cells, Cultured; Fibrosis; Kidney; Male; Mice; Mice, Inbred C57BL; Niacinamide; Nicotinamid | 2022 |
The significance of NAD + metabolites and nicotinamide N-methyltransferase in chronic kidney disease.
Topics: Animals; Female; Fibrosis; Humans; Male; Methionine; Mice; NAD; Niacinamide; Nicotinamide N-Methyltr | 2022 |
A Noninvasive Urine Metabolome Panel as Potential Biomarkers for Diagnosis of T Cell-Mediated Renal Transplant Rejection.
Topics: Acute Disease; Adenosine Diphosphate; Adult; Biomarkers; Cholesterol Esters; Cross-Sectional Studies | 2020 |
Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease.
Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Cisplatin; Disease Models, Animal; Disease Prog | 2021 |
Nicotinamide Attenuates the Progression of Renal Failure in a Mouse Model of Adenine-Induced Chronic Kidney Disease.
Topics: Adenine; Animals; Citric Acid Cycle; Disease Models, Animal; Disease Progression; Energy Metabolism; | 2021 |
Effect of NAD+ boosting on kidney ischemia-reperfusion injury.
Topics: Acute Kidney Injury; Animals; Autophagy; Disease Progression; Fibrosis; Glucuronidase; Kidney; Kloth | 2021 |
Magnesium but not nicotinamide prevents vascular calcification in experimental uraemia.
Topics: Animals; Cells, Cultured; Humans; Magnesium; Male; Mice; Mice, Inbred DBA; Muscle, Smooth, Vascular; | 2020 |
Intestinal phosphate absorption: The paracellular pathway predominates?
Topics: Animals; Clinical Trials as Topic; Diet, Western; Electrochemistry; Enterocytes; Humans; Hyperphosph | 2019 |
Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers.
Topics: Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Niacinamide; Phosphates; Renal Insu | 2019 |
Niacin and Chronic Kidney Disease.
Topics: Biological Transport; Bone Diseases; Cardiovascular Diseases; Dyslipidemias; Humans; Hyperphosphatem | 2015 |